STAT

DECEMBER 13, 2022

When it hit the market in 2013, the drug revolutionized the treatment of these cancers and represented a major step forward from chemotherapy and some other drugs at the time. NEW ORLEANS – One of the best therapies for some types of lymphoma and leukemia has been a drug called ibrutinib, made by AbbVie.

Chemotherapy 241

Chemotherapy 241

pharmaphorum

FEBRUARY 10, 2021

The PHERGain II study’s goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without compromising the clinical effectiveness of their treatment.

Chemotherapy 98

Chemotherapy Hospitals 98

STAT

NOVEMBER 14, 2023

So join us as we hoist the ever-present cup of stimulation — our choice today is gingerbread — and attack the fast-growing to-do list. Cisplatin is a type of chemotherapy drug used alone or in combination with other drugs to treat several advanced forms of cancer, including bladder, ovarian and testicular cancer.

Chemotherapy 311

Chemotherapy 311

Express Pharma

JANUARY 22, 2025

The company aims to reduce the toxic effects of chemotherapy and chances of cancer relapse improving the quality of lives of patients suffering from cancer. The company also plans to present its data for CDSCO approval, strengthen the team size along with expanding its product marketing and sales at a global level.

Chemotherapy 104

Chemotherapy 104

STAT

NOVEMBER 12, 2024

So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list. The medicine, Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies are investing in heavily.

Chemotherapy 230

Chemotherapy 230

Pharmacy Times

SEPTEMBER 16, 2024

Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.

Chemotherapy 52

Chemotherapy 52

Pharmafile

APRIL 17, 2023

Published date: 17/04/2023 Summary: Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented updated interim clinical efficacy data including subgroup analyses of first-line pancreatic cancer (PDAC) patients treated with the antibody nadunolimab (CAN04) and chemotherapy in the phase I/IIa CANFOUR trial. months; p=0.017).

Chemotherapy 52

Chemotherapy 52

epicur

MARCH 12, 2024

Epicur Pharma’s Advisory Council member Ann Donoghue, DVM, MS shares her personal perspective on the important relationship between veterinary oncology and compounded medications used in chemotherapy treatments. Many of the presentations discussed the chemotherapies available to treat dogs.

Compounding 52

Compounding Chemotherapy Compounding Pharmacies Labelling 52

pharmaphorum

MAY 30, 2022

pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advancing through precision medicine and targeted therapies. And once it’s present there, it’s taken up by the cancer cell.

Chemotherapy 116

Chemotherapy Immunity Immunization 116

pharmaphorum

DECEMBER 5, 2022

A vast majority of patients diagnosed with CRPC already present with metastases at the time of diagnosis. The findings will be presented at an upcoming medical meeting and submitted to the FDA for regulatory approval in 2023. Prostate cancer is the most frequently diagnosed cancer in men in 112 countries.

Chemotherapy 59

Chemotherapy Labelling Compounding Drug Development 59

European Pharmaceutical Review

NOVEMBER 7, 2023

These early data “indicate the potential for the anti-TIGIT, domvanalimab-based therapy to improve upon anti-PD-1 and chemotherapy in this setting, with a similar safety profile to anti-PD-1 and chemotherapy,” Dr Janjigian added. The treatment is being evaluated in patients with upper GI adenocarcinomas.

Chemotherapy 114

Chemotherapy 114

European Pharmaceutical Review

SEPTEMBER 15, 2023

Earlier this week on 11 September, while still known as Janssen Pharmaceutical Companies of Johnson & Johnson, the firm announced that RYBREVANT ® (amivantamab-vmjw) and Lazertinib plus chemotherapy provided a median progression-free survival (PFS) rate of 14 months in previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

Chemotherapy 98

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Packaging 98

European Pharmaceutical Review

MARCH 21, 2023

Historical SOC involves platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy (HDT) and stem cell transplant (ASCT) in patients who respond to salvage chemotherapy. According to Kite, these findings will be presented in full later this year at an upcoming scientific meeting.

Chemotherapy 145

Chemotherapy 145

European Pharmaceutical Review

NOVEMBER 21, 2024

Pills can present significant challenges for certain patients around administration, eg, for those who have difficulty swallowing liquids or solids. 2,3 In addition, the accessibility gap for treatment with pills can be widened by other factors such as the side effects of chemotherapy.

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

FEBRUARY 3, 2023

A Phase III clinical trial evaluating pembrolizumab with chemotherapy (carboplatin and paclitaxel), improved progression free survival (PFS) for stage III-IV or recurrent endometrial carcinoma. The full results of this trial will be presented at an upcoming scientific conference.

Chemotherapy 94

Chemotherapy 94

European Pharmaceutical Review

APRIL 24, 2024

Individuals with this aggressive brain cancer have limited treatment options, which include surgery, radiotherapy, chemotherapy, and best supportive care. Further to NICE’s present recommendation, last week, Novartis released promising new data for Fabhalta ® (iptacopan) as a treatment for the kidney disease IgA nephropathy (IgAN).

Chemotherapy 92

Chemotherapy 92

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results.

Chemotherapy 98

Chemotherapy Immunity Immunization 98

Pharmaceutical Technology

OCTOBER 3, 2022

On assessing zanubrutinib against the main therapies presently used by NHS England, the NICE committee noted that it was clinically effective as well as could aid WM patients to live longer. Current treatment options include chemotherapy and immunotherapy, but these can severely impact people’s quality of life.”.

Chemotherapy 105

Chemotherapy 105

Express Pharma

JUNE 13, 2024

China-based Innovent Biologics recently presented Phase I study results of its first-in-class anti-CLDN18.2/CD3 Currently, chemotherapy remains the mainstay of treatment across the first and second line for advanced pancreatic cancer. Recently, IBI343 Phase I clinical data (NCT05458219) was presented at ASCO.

Chemotherapy 105

Chemotherapy 105

European Pharmaceutical Review

OCTOBER 25, 2024

The biologic ZL-1310 is being investigated in an ongoing Phase Ia/Ib study in these patients who have had at least one platinum-based chemotherapy regimen. This initial data on ZL-1310 was presented this week at the EORTC-NCI-AACR (ENA) Symposium 2024.

Chemotherapy 97

Chemotherapy Compounding Immunity Immunization 97

Pharmaceutical Technology

SEPTEMBER 6, 2022

Updated using the pre|CISION technology, AVA6000 is a kind of generic chemotherapy doxorubicin. At present, AVA6000 is being analysed in a Phase I clinical trial underway to evaluate its safety and pharmacokinetics to potentially treat patients with various types of cancers, including soft tissue sarcoma.

Chemotherapy 98

Chemotherapy Drug Development 98

Pharmafile

MARCH 30, 2023

Janssen, part of Johnson & Johnson, has announce new long-term data from its CHRYSALIS study, which assessed Rybrevant (amivantamab) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease continued to progress while receiving platinum-based chemotherapy.

Chemotherapy 59

Chemotherapy 59

European Pharmaceutical Review

FEBRUARY 21, 2024

Future developments for lung cancer treatment TAGRISSO AstraZeneca stated that the data will be presented at a forthcoming medical meeting and distributed to regulators globally. TAGRISSO as a combination treatment with chemotherapy was recently approved in the US, based on data from the FLAURA2 Phase III trial.

Chemotherapy 105

Chemotherapy 105

pharmaphorum

JANUARY 26, 2023

Yescarta is administered to the patient via a single intravenous infusion following the administration of a round of chemotherapy designed to accommodate the new cells and minimise the patient’s immune reaction to them. About 50% will ultimately relapse post-transplant.

Chemotherapy 96

Chemotherapy Immunity Immunization Hospitals 96

Pharmacy Times

JUNE 12, 2023

Additionally, data from the SCARLET trial presented at ASCO 2023 indicate the safety and efficacy of sotorasib in combination with platinum-based chemotherapy treating non¬–small cell lung cancer.

Chemotherapy 49

Chemotherapy 49

pharmaphorum

MARCH 12, 2021

The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval for Retsevmo (selpercatinib) as monotherapy for adults with advance RET fusion-positive non-small cell lung cancer requiring systemic therapy after previous immunotherapy and/or chemotherapy treatment.

Chemotherapy 111

Chemotherapy Labelling 111

pharmaphorum

FEBRUARY 11, 2021

The filing is based on findings of the innovaTV 204 phase 2 single-arm trial, in 101 patients with recurrent or metastatic disease previously treated with doublet chemotherapy and Roche’s Avastin (bevacizumab) if appropriate. Tisotumab vedotin is made up of a toxic drug attached to the tail end of an antibody.

Chemotherapy 105

Chemotherapy 105

Express Pharma

FEBRUARY 19, 2024

per cent, CRC presents a significant growth opportunity. The key opinion leaders (KOLs) interviewed by GlobalData highlighted that tolerability remains a highly sought-after quality with developing therapies, as highly prescribed chemotherapies containing oxaliplatin often lead to serious adverse events and discontinuation.

Chemotherapy 105

Chemotherapy 105

European Pharmaceutical Review

JUNE 9, 2023

Then chemotherapy treatment was performed to eliminate their remaining bone marrow, providing space for the repaired cells to be infused back into their body afterwards. Preliminary clinical trial data is being presented at the European Haematology Association (EHA) Hybrid Congress in Germany.

Chemotherapy 98

Chemotherapy Hospitals 98

Pharmaceutical Business Review

JULY 10, 2024

It is to be used in combination with other antiemetic agents to prevent both acute and delayed nausea and vomiting following highly emetogenic cancer chemotherapy (HEC), including high-dose cisplatin, as well as with moderately emetogenic cancer chemotherapy (MEC).

Chemotherapy 59

Chemotherapy Biosimilars Hospitals 59

pharmaphorum

FEBRUARY 4, 2021

NICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with pemetrexed and platinum chemotherapy in certain lung cancer patients. It is therefore all the more important that clinicians have the best choices available for their patients.”.

Chemotherapy 59

Chemotherapy 59

Pharmaceutical Business Review

APRIL 25, 2024

GSK has received the US Food and Drug Administration’s (FDA) acceptance for its supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) along with standard-of-care chemotherapy (carboplatin and paclitaxel).

Chemotherapy 59

Chemotherapy 59

PharmaShots

JUNE 6, 2023

Shots: The P-III study (TROPiCS-02) evaluating Trodelvy vs CT in a ratio (1:1) in 543 patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and 2 chemotherapies In the exploratory analysis, improvement in m-OS benefit (14.5 vs 11.2mos.), PFS rates at 6/12/18mos. vs 29.4%)/ (21.7% vs 8.4%)/ (14.4%

Adverse Reactions 40

Adverse Reactions Chemotherapy 40

pharmaphorum

JANUARY 18, 2021

Until now people with AL amyloidosis have had to rely on chemotherapy, with its accompanying side effects, and other drugs to tackle organ failure once damage gets severe. Amyloid plaques can then form in multiple organs such as the heart, kidneys and liver, damaging them and in some cases leading to organ failure.

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

NOVEMBER 13, 2022

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) and platinum-based chemotherapy to treat Stage IV (metastatic) non-small cell lung cancer (NSCLC) in adults.

Chemotherapy 52

Chemotherapy Labelling Immunity Immunization 52

pharmaphorum

MARCH 21, 2022

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation to Exkivity (mobocertinib) as a monotherapy for non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR exon20 insertion mutations, after first-line chemotherapy.

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

MARCH 6, 2023

Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).

Chemotherapy 52

Chemotherapy Labelling Immunity Immunization 52